Many therapeutic options are now available for patients with multiple sclerosis. While the efficacy of each drug has been assessed against placebo or, more recently, against interferon, no direct comparisons of these new therapies have been conducted in randomized clinical trials. Therefore, indirect treatment comparisons are needed to inform clinical decisions. In this brief report, some basic concepts about network meta-analyses that are the formal methods used to run multiple indirect treatment comparisons are reviewed when applied in the context of multiple sclerosis studies.
LaupacisALillieEDueckA. Association between chronic cerebrospinal venous insufficiency and multiple sclerosis: A meta-analysis. CMAJ2011; 183: E1203–E1212.
2.
ZamboniPMenegattiEGaleottiR. The value of cerebral Doppler venous haemodynamics in the assessment of multiple sclerosis. J Neurol Sci2009; 282: 21–27.
3.
DoeppFPaulFValduezaJM. No cerebrocervical venous congestion in patients with multiple sclerosis. Ann Neurol2010; 68: 173–183.
4.
MayerCAPfeilschifterWLorenzMW. The perfect crime? Chronic cerebrospinal venous insufficiency not leaving a trace in MS. J Neurol Neurosurg Ps2011; 82: 436–440.
5.
SignoriASchiavettiIGalloF. Subgroups of multiple sclerosis patients with larger treatment benefits: A meta-analysis of randomized trials. Eur J Neurol2015; 22: 960–966.
6.
FilippiniGDel GiovaneCVacchiL. Immunomodulators and immunosuppressants for multiple sclerosis: A network meta-analysis. Cochrane Database Syst Rev2013; 6: CD008933.
7.
MikolDDBarkhofFChangP. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurol2008; 7: 903–914.
8.
TramacereIDel GiovaneCSalantiG. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: A network meta-analysis. Cochrane Database Syst Rev2015; 9: CD011381.
